Brokerages expect that Eiger BioPharmaceuticals, Inc. Piper Jaffray initiated the stock with "Overweight" rating in Monday, October 31 report.
Other analysts have also issued research reports about the company. Credit Suisse maintained Alder Biopharmaceuticals Inc (NASDAQ:ALDR) on Tuesday, March 29 with "Outperform" rating.
Eiger BioPharmaceuticals, Inc. (:EIGR)'s stock has performed at -20.60%. The stock of Celgene Corporation (NASDAQ:CELG) earned "Buy" rating by Jefferies on Friday, June 23. Aegis restated a buy rating and set a $41.00 target price on shares of Alder BioPharmaceuticals in a report on Tuesday, April 25th. Finally, Needham & Company LLC initiated coverage on Alder BioPharmaceuticals in a research note on Monday, May 15th. The stock presently has a consensus rating of Buy and a consensus price target of $35.00. Finally, Wells Fargo & Company reaffirmed an "outperform" rating and set a $51.00 target price on shares of Alder BioPharmaceuticals in a report on Wednesday, June 28th. The firm's market capitalization is $604.92 million. The company's 50-day moving average price is $17.14 and its 200 day moving average price is $20.51. Eiger BioPharmaceuticals has a one year low of $6.10 and a one year high of $20.63.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Thursday, April 27th.
Analysts expect Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to report $-1.71 EPS on July, 25.They anticipate $0.92 EPS change or 116.46% from last quarter's $-0.79 EPS. Over the last three months, the shares of the company have changed 8.82% and performed -21.28% over the last six months. After having $-1.99 EPS previously, Alder Biopharmaceuticals Inc's analysts see -14.07% EPS growth.
ILLEGAL ACTIVITY NOTICE: This piece was reported by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of U.S. and worldwide copyright and trademark law. The original version of this piece can be accessed at https://www.baseball-news-blog.com/2017/07/17/alder-biopharmaceuticals-inc-nasdaqaldr-upgraded-to-buy-by-zacks-investment-research.html.
Large investors have recently bought and sold shares of the stock. State Street Corp now owns 1,758,687 shares of the biopharmaceutical company's stock worth $36,579,000 after buying an additional 268,187 shares during the period. Endurant Capital Management LP purchased a new stake in shares of Alder BioPharmaceuticals during the first quarter valued at about $763,000. Credit Suisse AG now owns 243,807 shares of the biopharmaceutical company's stock worth $5,071,000 after buying an additional 40,260 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Eiger BioPharmaceuticals by 4.7% in the first quarter. Guggenheim Capital LLC now owns 89,980 shares of the biopharmaceutical company's stock worth $1,872,000 after buying an additional 7,472 shares during the period. Hikari Power Ltd acquired a new position in shares of Eiger BioPharmaceuticals during the first quarter valued at approximately $118,000. Redmile Group LLC increased its stake in shares of Alder BioPharmaceuticals by 107.5% in the first quarter. Redmile Group LLC now owns 1,909,886 shares of the biopharmaceutical company's stock worth $39,726,000 after buying an additional 989,336 shares during the period.